openPR Logo
Press release

CAR-T Cell Therapy Market Research, Recent Trends And Growth Forecast 2026: Bluebird Bio (US), Celgene Corporation (US), Gilead Sciences, Inc. (US), Cellectis (France), Servier Laboratories (France), Pfizer Inc. (US), Mereck KGaA (Germany), Amgen Inc. (US

04-01-2020 05:24 PM CET | Health & Medicine

Press release from: Polaris Market Research & Consulting

CAR-T Cell Therap Industry

CAR-T Cell Therap Industry

CAR-T Cell Therapy Market report provides a thoroughly researched abstract of the key players with considerable shareholdings at a global level regarding demand, sales, and income by providing better products and services. Research Report outlines a forecast for the CAR-T Cell Therapy market between 2020 and 2026. In terms of value, the CAR-T Cell Therapy industry is expected to register a steady CAGR during the forecast period.

According to the analysis by Polaris Market Research, the potential of the market is ~ $9 billion by 2026, with major focus on Diffuse Large B-Cell Lymphoma (DLBCL) indication in 2020-21. However, it is expected that the market would also start focusing on Multiple Myeloma (MM) indication and the market for the same is expected to grow at a compounded annual growth rate of more than 80% from 2020 to 2026.

Request a Sample Copy@ https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/request-for-sample

The key players covered in this study
o Pfizer Inc
o Bluebird Bio
o Celgene Corporation
o Gilead Sciences
o Cellectis
o Servier Laboratories
o Mereck KGaA
o Amgen Inc
o Intellia Therapeutics
o Novartis International AG
o Caribou Biosciences, Inc
o Celyad
o Bellicum Pharmaceuticals
o Noile-Immune Biotech
o Nanjing Legend Biotechnology Co
o Johnson & Johnson
o Sangamo Therapeutics, Inc

Market segment by Type, the product can be split into
o CD 19
o CD 20
o GD2
o CD22
o CD30
o CD33
o HER1
o HER2
o Meso
o EGFRvlll

Market segment by Application, split into
o Healthcare
o Others

Get Offer on Report: https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/request-for-discount-pricing

It is estimated that U.S. is one of the major markets for CAR-T Cell Therapy due to continuous R&D happening in this region also backed by ongoing regulatory approvals of the new therapies. Along with the new therapy developments, companies are also focusing on establishing centers for cancer awareness and how this novel therapy would help in cancer treatment. This would help the market to grow in this region. The European region is also expected to closely follow by U.S. wherein European Medicine Agencies (EMA) have approved Kymriah and Yescarta which is expected to push the market for further growth in this region. However, the market for Asia Pacific is at its early stages wherein Ministry of Health, Labor and Welfare (MHLW) of Japan is the first regulatory authority to approve Kymriah in APAC.

It can be seen that the business scenario of the market is dynamic and major companies are competing with each other to increase their market share in the major geographies of U.S. and Europe. For example, Novartis and Gilead came-up with 33 and 28 authorized centers respectively in U.S. Some of the major companies in this space such as Celgene are expected to file for FDA approvals for two more CAR-Ts lisocabtagene maraleucel in lymphoma and bb2121 (idecabtagene vicleucel) in myeloma.

Along with opening new centers and acquiring necessary government approvals, the companies are also focusing on partnerships, acquisitions and mergers. For instance, Celgene acquired Juno Therapeutics in November 2020 for approximately $9 billion in 2020 and further Bristol-Myers Squibb completed its acquisition of Celgene in November 2019.

Else place an Inquire before Purchase "Global CAR-T Cell Therapy Market Size, Status and Forecast 2026: https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/inquire-before-buying

About Us

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world

Get n Touch:
Mr. Likhil
Corporate Sales
Polaris Market Research
Phone: 1-646-568-9980
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release CAR-T Cell Therapy Market Research, Recent Trends And Growth Forecast 2026: Bluebird Bio (US), Celgene Corporation (US), Gilead Sciences, Inc. (US), Cellectis (France), Servier Laboratories (France), Pfizer Inc. (US), Mereck KGaA (Germany), Amgen Inc. (US here

News-ID: 1995265 • Views:

More Releases from Polaris Market Research & Consulting

Europe Armor Materials Market to Reach USD 6.09 Billion by 2034, Growing at 7.0% CAGR
Europe Armor Materials Market to Reach USD 6.09 Billion by 2034, Growing at 7.0% …
Market Size and Share: Europe Armor Materials Market is currently valued at USD 3.10 billion in 2024 and is anticipated to generate an estimated revenue of USD 6.09 billion by 2034, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 7% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2025 - 2034 Polaris Market Research has introduced the latest market research
Europe Antibody Specificity Testing Market Projected to Hit USD 433.81 Million by 2034, Growing at a CAGR of 7.3%
Europe Antibody Specificity Testing Market Projected to Hit USD 433.81 Million b …
The quantitative market research report published by Polaris Market Research on Europe Antibody Specificity Testing Market aims to educate users with an in-depth understanding of a rapidly growing market. The study details important facts and figures, expert opinions, and major developments across the globe. The research study serves as a vital source of information with the historical data, Europe Antibody Specificity Testing Market size, financial data, and projected future growth.
U.S. Extended Detection and Response (XDR) Market to Reach USD 24.86 Billion by 2034, Advancing at a CAGR of 30.6%
U.S. Extended Detection and Response (XDR) Market to Reach USD 24.86 Billion by …
The quantitative market research report published by Polaris Market Research on U.S. Extended Detection and Response (XDR) Market aims to educate users with an in-depth understanding of a rapidly growing market. The study details important facts and figures, expert opinions, and major developments across the globe. The research study serves as a vital source of information with the historical data, U.S. Extended Detection and Response (XDR) Market size, financial data,
Europe Ethylene Propylene Diene Monomer (EPDM) Market Set to Reach USD 1.52 Billion by 2034, Expanding at 4.1% CAGR
Europe Ethylene Propylene Diene Monomer (EPDM) Market Set to Reach USD 1.52 Bill …
The quantitative market research report published by Polaris Market Research on Europe Ethylene Propylene Diene Monomer (EPDM) Market aims to educate users with an in-depth understanding of a rapidly growing market. The study details important facts and figures, expert opinions, and major developments across the globe. The research study serves as a vital source of information with the historical data, Europe Ethylene Propylene Diene Monomer (EPDM) Market size, financial data,

All 5 Releases


More Releases for Therap

Multiple Myeloma Market Statistics Expected to Experience Major Growth by 2034, …
The Key Multiple Myeloma Companies in the market include - Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., CASI Pharmaceuticals, Sorrento Therapeutics, Johnson & Johnson Innovative Medicine, Bristol-Myers Squibb and Bluebird bio, Sanofi, and others. DelveInsight's "Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Multiple Myeloma, historical and forecasted epidemiology as well as the Multiple Myeloma market trends in the United States, EU4
Urea Cycle Disorders Pipeline 2025: Innovative Clinical Developments by 8+ Globa …
DelveInsight's, "Urea Cycle Disorders - Pipeline Insight, 2025," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Urea Cycle Disorders pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. With urea cycle disorders becoming increasingly prevalent worldwide
Natural Killer Cell Therapies Clinical Trials, Companies, Therapeutic Assessment …
DelveInsight's, "Natural Killer Cell Therapies - Pipeline Insight, 2025," report provides comprehensive insights about 100+ companies and 140+ pipeline drugs in Natural Killer Cell Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. DelveInsight reports that over 100 key
Hemophilia Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatm …
DelveInsight's, "Hemophilia- Pipeline Insight, 2025," report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Hemophilia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Hemophilia Pipeline constitutes 80+ key companies continuously working towards developing 80+ Hemophilia treatment
Autosomal Dominant Polycystic Kidney Disease Market Forecasted to Surge in Comin …
The Key Autosomal Dominant Polycystic Kidney Disease Companies in the market include - Otsuka America Pharmaceuticals, Vertex Pharmaceuticals, Pfizer, Otsuka Pharma, Palladio Biosciences, Novartis Pharma, XORTX Therapeutic, Reata Pharmaceuticals, Kyowa Kirin, Sanofi, Galapagos NV, Janssen Pharmaceuticals, Regulus Therapeutics, and others. DelveInsight's "Autosomal Dominant Polycystic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Autosomal Dominant Polycystic Kidney Disease, historical and forecasted epidemiology as well as
Empowering Growth: Bedaquiline Fumarate Medications Market 2024 and Industry Seg …
The latest research study released by Worldwide Market Reports on "Bedaquiline Fumarate Medications Market 2024 Forecast to 2031" research provides accurate economic, global, and country-level predictions and analyses. It provides a comprehensive perspective of the competitive market as well as an in-depth supply chain analysis to assist businesses in identifying major changes in industry practices. The market report also examines the current state of the Bedaquiline Fumarate Medications industry, as